APR 11, 2018 12:00 PM PDT

Emerging Trends: Cell Free (cf)DNA-Based Screening for Common Aneuploidies

Speaker
  • Professor, Department of Pathology and Laboratory Medicine, Women & Infants Hospital/Alpert Medical School at Brown University
    BIOGRAPHY

Abstract

Screening for Down syndrome began with the question "How old will you be when you deliver?".  If the pregnant woman answered 35 years of age or older, she was offered amniocentesis and a karyotype (diagnostic testing). Since then, serum markers in the second trimester have been used to form the Quadruple test.  While in the first trimester the ultrasound  and serum markers are identified as the Combined test.  When results from both trimester are used, this is termed the integrated test.  The integrated test has about a 90% detection rate for a 2% false positive rate and was the highest performing test until 2011.  It is important to note that these are phenotypic-based tests.  The finding in 1997 that cfDNA from the feto-placenta unit was in the maternal circulation in a relatively high percentage, allowed for the eventual development of a screening test, once next generation sequencing was available.  It is now clear that cfDNA can detect about 99% of Down syndrome with a false positive rate of 1 or 2 per thousand.  Importantly, this is a genotypic-based test.  Since 2013, cfDNA screening has been routinely used as a secondary screening test in 'high risk' pregnancies.  High detection means that  most of these women will have a negative result and would likely avoid invasive testing.  The low false positive rate means the predictive value will be high.  Current cfDNA screening tests tend to focus on common autosomal aneuploidies, with some expanding coverage to the sex chromosomes.  Recently, laboratories have extending testing to other chromosomes as well as to a limited number of microdeletion syndromes.  However reduced costs and less complexity are needed to allow cfDNA screening to be offered as a first line prenatal test to the entire pregnancy population.  Some tests are now emerging that aim at reducing costs and complexity.  In addition, there are competing methodologies that can identify a broader array of disorders.


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
APR 21, 2021 10:00 AM PDT
C.E. CREDITS
APR 21, 2021 10:00 AM PDT
Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
JUN 22, 2021 10:00 AM PDT
C.E. CREDITS
JUN 22, 2021 10:00 AM PDT
Date: June 22, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Antimicrobial resistance (AMR) has emerged as one of the principal public health problems of the 21st century. It threatens the effectiv...
JUL 15, 2021 9:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
JUL 15, 2021 9:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Date: July 15, 2021 Time: 9:00am (PDT), 12:00pm (EDT) The Pisces workflow robust, easy-to-use, end-to-end multi-omics solution for highly multiplexed targeted Spatial RNA analysis. VeranomeB...
APR 20, 2021 11:00 AM PDT
C.E. CREDITS
APR 20, 2021 11:00 AM PDT
Date: April 20, 2021 Time: 11:00am (PST), 2:00pm (EST) Identification and confirmation of microbial isolates is crucial in the analysis workflow, providing decision-makers the information...
APR 11, 2018 12:00 PM PDT

Emerging Trends: Cell Free (cf)DNA-Based Screening for Common Aneuploidies


Specialty

Pcr

Oncology

Gene Sequencing

Drug Discovery

Mass Cytometry

Cell Culture

T-Cells

Biotechnology

Immunotherapeutics

Antibodies

Virology

Immunology

Dna Sequencing

Personalized Medicine

Clinical Diagnostics

Geography

North America50%

Europe50%

Registration Source

Website Visitors100%

Job Title

Student50%

Medical Laboratory Technician50%

Organization

Ambulatory Care50%

Academic Institution50%


Show Resources
Loading Comments...
Show Resources
Attendees
  • See more